Avery Therapeutics is dedicated to developing regenerative medicine therapies to improve quality of life worldwide. Avery’s tissue engineering platform technology provides a robust delivery systems for cell therapy. Avery’s lead product, MyCardia™, is an allogeneic, cryopreserved, multi cell type, (including iPSC-derived cardiomyocytes) engineered heart tissue. MyCardia is in the pre-clinical development stage for the treatment of chronic heart failure and is targeted to reach clinical trials in 2019. Avery’s use of an allo-iPSC source in combination with the ability to cryopreserve product enables large scale cost-effective manufacturing and an optimal supply chain for off the shelf availability. Avery is seeking partners for development of new regenerative medicine, engineered tissue products. Avery’s management includes George Dunbar, MBA, Executive Chairman, Jen Koevary, PhD, COO/CFO, Jordan Lancaster, PhD, CSO, and Steven Goldman, MD, CMO.